by TractManager | Feb 28, 2024 | Emerging Technology Report
Nemolizumab (Galderma) is a subcutaneously injected interleukin-31 receptor alpha antagonist under investigation for the treatment of adult patients with prurigo nodularis.
by TractManager | Feb 28, 2024 | Emerging Technology Report
Donanemab (Eli Lilly and Co.) is an investigational, intravenously administered amyloid beta-directed antibody proposed for the treatment of Alzheimer disease.
by TractManager | Feb 27, 2024 | Emerging Technology Report
Lifileucel (Amtagvi; Iovance Biotherapeutics Inc.) is a tumor-derived autologous T cell immunotherapy indicated for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation...
by TractManager | Feb 26, 2024 | Evolving Evidence Review
This report addresses whether full-text clinical studies, systematic reviews, and clinical practice guidelines and position statements support the use of the currently available design of the ApiFix (ApiFix Ltd.) minimally invasive deformity correction system for...
by TractManager | Feb 22, 2024 | Evolving Evidence Review
This report addresses whether full-text clinical studies, systematic reviews, and clinical practice guidelines and position statements support the use of Kerecis Omega3 Wound (Kerecis) fish skin grafts for treatment of burns.
Recent Comments